Refine by MP, party, committee, province, or result type.
Industry committee Thank you, Mr. Chair and members of the committee, for permitting me to testify about why, in my opinion, Bill C-393 fails to comply with Canada's international treaty obligations. I am a partner at Gowling Lafleur Henderson. I have practised international trade law for over thr
October 26th, 2010Committee meeting
Richard Dearden
Industry committee Because it's important to understand what happened when Apotex responded to Rwanda's notification, I'll give you some dates, members. July 2007, Rwanda notified the WTO, as it's required to do under the decision. Apotex applied for a CAMR authorization on September 4, 2007. T
October 26th, 2010Committee meeting
Richard Dearden
Industry committee I'll go in reverse. The compulsory licence obligations are set out in article 31 of the TRIPS agreement. That goes from paragraph (a) to paragraph (l) in terms of conditions that must be met for a member such as Canada to authorize compulsory licences. One of those that I menti
October 26th, 2010Committee meeting
Richard Dearden
Industry committee I will. I told the committee that Apotex had the authorization on September 17, 2007, to export 15.6 million tablets to Rwanda, because that's what the authorization let them do. It took them a total of two years to ship that. CAMR worked, committee members. They got their licen
October 26th, 2010Committee meeting
Richard Dearden
Industry committee I think Professor Abbott was fair in saying that there is no fine. That's true. But does Canada respect its international treaty obligations? It just signed up to make the waiver a permanent amendment to TRIPS. In my opinion, it matters that Canada would comply with its internati
October 26th, 2010Committee meeting
Richard Dearden
Industry committee There's a third one to my left.
October 26th, 2010Committee meeting
Richard Dearden
Industry committee The requirement in CAMR now for Health Canada approval actually isn't mandated by the general council decision, but I don't think anybody, the generics or the innovative drug industry, object to the requirement being in there that safe drugs actually do get exported under the com
October 26th, 2010Committee meeting
Richard Dearden